Session » (1052–1081) Immunological Complications of Medical Therapy Poster

Date: Monday, November 13, 2023

Time: 9:00AM-11:00AM

Meeting: ACR Convergence 2023

9:00AM-11:00AM: Abstract Number: 1067

A Comparison of Joint Involvement Patterns in Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis and Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1077

Anti-drug Antibodies Formation During Tapering and Stopping of Methotrexate in Rheumatoid Arthritis Patients with Longstanding Use of Adalimumab

9:00AM-11:00AM: Abstract Number: 1062

Antiretinal Autoantibodies in Hydroxychloroquine Eye Toxicity

9:00AM-11:00AM: Abstract Number: 1065

Association Between COVID-19 and Disease-Modifying Antirheumatic Drugs

9:00AM-11:00AM: Abstract Number: 1074

Baseline Clinical Features, but Not Shared Epitope or HLA B27, Predict Severe Outcomes for Immune Checkpoint Inhibitor-induced Inflammatory Arthritis

9:00AM-11:00AM: Abstract Number: 1066

Biologic Drug and Anti-Drug Antibody Monitoring: All 5 TNF-Inhibitors, Infliximab, Adalimumab, Golimumab, Etanercept, Certolizumab Pegol, in 63,930 Patient Samples

9:00AM-11:00AM: Abstract Number: 1055

Cancer Outcomes in Cancer Patients with Immune Checkpoint Inhibitor-induced Inflammatory Arthritis Treated with Glucocorticoids: Data from the CanRIO Retrospective Cohort

9:00AM-11:00AM: Abstract Number: 1081

Clinical Consequences of Infliximab Immunogenicity and the Impact of Proactive Therapeutic Drug Monitoring: Secondary Analyses of a Randomised Clinical Trial

9:00AM-11:00AM: Abstract Number: 1069

Exploring the Risk of Demyelination Associated with TNF Alpha Inhibitors: Analysis of the FDA Adverse Event Reporting System (FAERS)

9:00AM-11:00AM: Abstract Number: 1079

Identification of Immune Checkpoint Inhibitor-Induced Myositis Patients Using Electronic Health Records Is Most Successful When Employing Multiple Data Elements

9:00AM-11:00AM: Abstract Number: 1059

Identification of Patients with Immune Checkpoint Inhibitor-Associated Inflammatory Arthritis Using Medicare Claims Data

9:00AM-11:00AM: Abstract Number: 1054

Immune Checkpoint Inhibitor Induced Polymyalgia Rheumatica Demonstrates a Similar Scintigraphic Appearance to Classical Polymyalgia Rheumatica on 18F-Fluorodeoxyglucose PET/CT

9:00AM-11:00AM: Abstract Number: 1056

Immune Checkpoint Inhibitor Rechallenge in Patients Who Previously Experienced Immune-Related Inflammatory Arthritis: A Multicenter Observational Study

9:00AM-11:00AM: Abstract Number: 1063

Impact of Aging on Rheumatic Immune-related Adverse Events Secondary to Immune Checkpoint Inhibitors: Experience from the Canadian Research Group of Rheumatology in Immuno-Oncology (CanRIO)

9:00AM-11:00AM: Abstract Number: 1075

Impact of Immunosuppression on the Safety and Efficacy of Immune Checkpoint Inhibitors in Patients with Rheumatic Autoimmune Disease: Experience from the Canadian Research Group of Rheumatology in Immuno-Oncology (CanRIO)

9:00AM-11:00AM: Abstract Number: 1060

Impact of Troponin Monitoring on Cardiac Outcomes in Patients Receiving Immune Checkpoint Inhibitors

9:00AM-11:00AM: Abstract Number: 1072

Increase in Major Osteoporotic Fractures After Therapy with Immune Checkpoint Inhibitors

9:00AM-11:00AM: Abstract Number: 1057

Melanoma and Combination Immune Checkpoint Inhibitors Are More Clearly Associated with the Development of Chronic Inflammatory Arthritis Than Pre-existing Autoimmune Disease: A Cross-Sectional Study of Administrative Health Data

9:00AM-11:00AM: Abstract Number: 1068

Multidisciplinary Prospective Study of Patients Treated with Immune Checkpoint Inhibitors Who Developed Rheumatic Immune-related Adverse Events

9:00AM-11:00AM: Abstract Number: 1071

No Increase in Mortality in US Veterans with Rheumatoid Arthritis Treated with Immune Checkpoint Inhibitors (ICIs)

9:00AM-11:00AM: Abstract Number: 1078

Outcomes of COVID-19 Infection in Hospitalized Autoimmune Patients and Transplant Patients on Immunosuppression

9:00AM-11:00AM: Abstract Number: 1053

Outcomes of Immune Check Point Inhibitor Use in US Veterans with Pre-Existing Inflammatory Muscle Disease

9:00AM-11:00AM: Abstract Number: 1080

Prevalence and Incidence of Paradoxical Side-effects of TNF-α Inhibitors: A Cross-sectional Study

9:00AM-11:00AM: Abstract Number: 1058

Resolution of Immune Checkpoint Inhibitors-Induced Inflammatory Arthritis While Maintaining Active Treatment with Checkpoint Inhibitors

9:00AM-11:00AM: Abstract Number: 1073

Risk of Inflammatory Central Nervous System Diseases Among New Users of Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drugs

9:00AM-11:00AM: Abstract Number: 1076

Rituximab-Associated Hypogammaglobulinemia in Patients with Rheumatic Diseases: A Multicenter Retrospective Observational Study

9:00AM-11:00AM: Abstract Number: 1070

Safety of DMARDs in Rheumatologic Immune-related Adverse Events Associated with Immune Checkpoint Inhibitors: Data from a Monocentric Cohort in Hospices Civils De Lyon

9:00AM-11:00AM: Abstract Number: 1064

Seroconversion Rates in Rituximab-Treated Rheumatic Patients Receiving COVID-19 Vaccination

9:00AM-11:00AM: Abstract Number: 1052

Unique Cellular and Autoantibody Signatures in Patients with irAEs Revealed by Longitudinal Immune Tracking

9:00AM-11:00AM: Abstract Number: 1061

Vasculitis as an Immune-Related Adverse Event: Unraveling the Complexities at the Intersection of Immunology and Vascular Pathology

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].